Filter Results:
(10)
Show Results For
- All HBS Web
(15)
- Faculty Publications (10)
Show Results For
- All HBS Web
(15)
- Faculty Publications (10)
Page 1 of 10
Results
- September 2022
- Article
Find and Replace: R&D Investment Following the Erosion of Existing Products
By: Joshua L. Krieger, Xuelin Li and Richard T. Thakor
How do innovative firms react when existing products experience negative shocks? We explore this question with detailed project-level data from drug development firms. Using FDA Public Health Advisories as idiosyncratic negative shocks to approved drugs, we first... View Details
Keywords: R&D Investments; Drug Development; Product Shocks; M&A; Biopharmaceutical Industry; FDA; System Shocks; Research and Development; Investment; Decision Making; Pharmaceutical Industry
Krieger, Joshua L., Xuelin Li, and Richard T. Thakor. "Find and Replace: R&D Investment Following the Erosion of Existing Products." Management Science 68, no. 9 (September 2022): 6552–6571.
- 2020
- Working Paper
Short-Termism, Shareholder Payouts, and Investment in the EU
By: Jesse M. Fried and Charles C.Y. Wang
Investor-driven “short-termism” is said to harm EU public firms' ability to invest for the long term, prompting calls for the EU to better insulate managers from shareholder pressure. But the evidence offered—in the form of rising levels of repurchases and dividends—is... View Details
Keywords: Short-termism; Quarterly Capitalism; EU; Dividends; Equity Issuances; Equity Compensastion; Capital Flows; Capital Distribution; R&D; Innovation; Investment; Corporate Governance; Investment Return; Acquisition; European Union
Fried, Jesse M., and Charles C.Y. Wang. "Short-Termism, Shareholder Payouts, and Investment in the EU." Harvard Business School Working Paper, No. 21-054, October 2020.
- Article
Lessons From Hollywood: A New Approach To Funding R&D
By: Gary P. Pisano and Andrew W. Lo
Companies find it increasingly difficult to justify long-term, risky R&D investments—particularly in science-based fields such as biotechnology, advanced materials, and energy. We argue in this article that the traditional venture model has limits for such investments... View Details
Keywords: Financial Innovation; Financial Strategy; Project Management; R&D; Start-up; Innovation Strategy; Business Model; Research and Development; Financial Management; Risk Management; Strategy
Pisano, Gary P., and Andrew W. Lo. "Lessons From Hollywood: A New Approach To Funding R&D." MIT Sloan Management Review 57, no. 2 (Winter 2016): 47–54.
- December 2016 (Revised December 2018)
- Case
From Start-Up to Grown-Up Nation: The Future of the Israeli Innovation Ecosystem
By: Elie Ofek and Margot Eiran
In June 2016, Benjamin (Bibi) Netanyahu, Prime Minister of Israel, wrestled with how to sustain Israel’s strong innovation track record and the country’s reputation as the “startup nation.” Despite the economic miracle the country had wrought since its founding, he... View Details
Keywords: Israel; Israeli Start-up Nation; Innovation Economy; Entrepreneurial Mindset; Scaling-up; Unicorns; Innovation Clusters; High-tech; Innovation Management; Multinational Corporation R&D Centers; Social Equality; Two-tier Economy; Liberalizing An Economy; Foreign Investment; Military Service; Quality Of Human Capital; Socioeconomic Gaps; Labor Force Participation; Government Initiatives; Innovation and Management; Entrepreneurship; Venture Capital; Business Startups; Government and Politics; Economy; Equality and Inequality; Education; Resource Allocation; Globalization; Israel
Ofek, Elie, and Margot Eiran. "From Start-Up to Grown-Up Nation: The Future of the Israeli Innovation Ecosystem." Harvard Business School Case 517-066, December 2016. (Revised December 2018.)
- January 2016 (Revised January 2019)
- Supplement
The Allergan Board Under Fire (B)
By: Lynn S. Paine, Suraj Srinivasan, John C. Coates and David Lane
In 2014, the Allergan Inc. board of directors received a surprise takeover offer from Valeant Pharmaceuticals in alliance with hedge fund activist Bill Ackman's Pershing Square Capital Management. In the unprecedented arrangement between an acquirer and a hedge fund... View Details
Keywords: Allergan, Inc.; Valeant; Ackman; Pershing Square; Tender Offer; Activist Investors; Business Models; R&D; Board Of Directors; Securities Litigation; Acquisition Strategy; Takeover Defenses; Hedge Funds; Shareholder Rights; Proxy Contest; Shareholder Special Meetings; Legal Issues In Contested Takeovers; Corporate Governance; Investment Activism; Business and Stakeholder Relations; Business Model; Business and Shareholder Relations; Valuation; Pharmaceutical Industry
Paine, Lynn S., Suraj Srinivasan, John C. Coates, and David Lane. "The Allergan Board Under Fire (B)." Harvard Business School Supplement 316-029, January 2016. (Revised January 2019.)
- February 2015
- Case
TouchTunes and the Connected Digital Jukebox Platform
By: Alan MacCormack and Noah Fisher
The case describes innovation and new product development at TouchTunes, the leader in the Digital Jukebox market. In March 2013, after releasing its innovative "Virtuo" jukebox developed in collaboration with frog design, TouchTunes was at a crossroads. Having... View Details
- September 2013 (Revised November 2015)
- Case
Living Proof: Are We a Technology Company or a Beauty Company?
By: Willy Shih
Jon Flint came up with the idea of a science-based beauty company while talking with his hairdresser about the problems with typical hair and skin care products. Together with a small team that included Professor Robert Langer of MIT, he committed to assemble a team... View Details
Keywords: Hair Care; Personal Care; Science-based; R&D; Innovation and Invention; Innovation and Management; Innovation Leadership; Innovation Strategy; Technological Innovation; Marketing; Marketing Strategy; Product Marketing; Product Positioning; Science-Based Business; Business Strategy; Commercialization; Corporate Strategy; Technology Platform; Expansion; Beauty and Cosmetics Industry; United States; Boston; Cambridge
Shih, Willy. "Living Proof: Are We a Technology Company or a Beauty Company?" Harvard Business School Case 614-013, September 2013. (Revised November 2015.)
- March 2013
- Article
Misvaluing Innovation
By: Lauren Cohen, Karl Diether and Christopher Malloy
We demonstrate that a firm's ability to innovate is predictable, persistent, and relatively simple to compute, and yet the stock market ignores the implications of past successes when valuing future innovation. We show that two firms that invest the exact same in... View Details
Keywords: Innovation; Return Predictability; R&D; Information; Forecasting and Prediction; Research and Development; Innovation and Invention
Cohen, Lauren, Karl Diether, and Christopher Malloy. "Misvaluing Innovation." Review of Financial Studies 26, no. 3 (March 2013): 635–666.
- November 2012
- Case
CSIRO: The Light Metals Flagship Decision
By: Willy Shih, Margaret P. Pierson and Dawn Lau
This case explores the challenge of investing in basic research as a public good. CSIRO was Australia's leading science and research agency, and it was chartered to enhance national prosperity through R&D. Its Flagships program was designed to align research interests... View Details
Keywords: R&D; Basic Research; Government-funded Research; Public Goods; Extractive Industries; Metals; Metals Processing; Decision Choices and Conditions; Decisions; Globalized Markets and Industries; Growth and Development; Innovation Strategy; Technological Innovation; Research and Development; Science-Based Business; Technology Adoption; Technology Platform; Manufacturing Industry; Mining Industry; Oceania; Australia
Shih, Willy, Margaret P. Pierson, and Dawn Lau. "CSIRO: The Light Metals Flagship Decision." Harvard Business School Case 613-029, November 2012.
- April 2012
- Case
Bella Healthcare India
By: Dorothy Leonard and Sunru Yong
Bella Healthcare India was originally established in Bangalore as a low-cost manufacturing facility for a U.S.-based cardiology equipment developer. Under country manager Joseph Cherian it evolved considerably, developing its own research and development capabilities.... View Details
Keywords: India; Productivity; Organizational Development; International Business; R&D; Cross-cultural Relations; Medical Equipment & Devices; Joint Ventures; Medical Specialties; Research and Development; Product Development; Organizational Change and Adaptation; Strategy; Decision Choices and Conditions; Health Care and Treatment; Product Launch; Failure; Cross-Cultural and Cross-Border Issues; Medical Devices and Supplies Industry; Bangalore
Leonard, Dorothy, and Sunru Yong. "Bella Healthcare India." Harvard Business School Brief Case 124-440, April 2012.